Lv3
230 积分 2025-03-13 加入
Physicochemical and functional characterization of trastuzumab-dkst, a trastuzumab biosimilar
3天前
已完结
Physicochemical stability of PF-05280014 (trastuzumab-qyyp; TrazimeraTM), a trastuzumab biosimilar, under extended in-use conditions
3天前
已完结
Effect of formulation composition on trastuzumab stability
4天前
已完结
An Automated Tool for Glycosimilarity Assessment of mAb Therapeutic Biosimilars: Trastuzumab and Bevacizumab as Case Studies
4天前
已完结
From cell line development to the formulated drug product: The art of manufacturing therapeutic monoclonal antibodies
15天前
已完结
Analytical comparability demonstrated for an IgG4 molecule, inclacumab, following transfer of manufacturing responsibility from Roche to Global Blood Therapeutics
15天前
已完结
Risk-Based Approach for Analytical Comparability and Comparability Protocols
15天前
已完结
An Industry Perspective on the use of Forced Degradation Studies to Assess Comparability of Biopharmaceuticals
16天前
已完结
Assessment of Availability, Clinical Testing, and US Food and Drug Administration Review of Biosimilar Biologic Products
16天前
已完结
Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents
16天前
已完结
皖公网安备34019202002308
